0.12Open0.12Pre Close0 Volume4 Open Interest9.00Strike Price0.00Turnover216.35%IV122.44%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.1305Delta0.0927Gamma34.17Leverage Ratio-0.0099Theta0.0003Rho4.46Eff Leverage0.0022Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet